List of Sublocade drug patents

Sublocade is owned by Indivior Inc.

Sublocade contains Buprenorphine.

Sublocade has a total of 11 drug patents out of which 0 drug patents have expired.

Sublocade was authorised for market use on 30 November, 2017.

Sublocade is available in solution, extended release;subcutaneous dosage forms.

Sublocade can be used as treating addiction with 100 mg or 300 mg dose of buprenorphine; treating opioid addiction by administering buprenorphine; treating addiction by once per month administration of buprenorphine; treating addiction by subcutaneous injection of buprenorphine, treating opioid addiction by administering buprenorphine; treating opioid addiction by administering buprenorphine once per month; treating opioid addiction by administering buprenorphine composition with 28 day dose duration; treating opioid addiction by subcutaneous injection of buprenorphine, treating opioid dependency by administering buprenorphine once per month; treating opioid dependence by administering buprenorphine, treating opioid use disorder, treating opioid dependency by administering buprenorphine; treating opioid dependency by administering buprenorphine once monthly, in situ formation of solid buprenorphine composition, treating opioid dependency by administering buprenorphine; treating opioid addiction by administration of buprenorphine; treating opioid dependency by subcutaneously administering buprenorphine; treating opioid addiction by 100 mg or 300 mg dose buprenorphine; treating opioid dependency by administering buprenorphine once per month, treatment of moderate to severe opioid use disorder.

The generics of Sublocade are possible to be released after 22 June, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10198218 INDIVIOR INC Injectable flowable composition comprising buprenorphine
Jun, 2031

(8 years from now)

US9272044 INDIVIOR INC Injectable flowable composition buprenorphine
Jun, 2031

(8 years from now)

US9498432 INDIVIOR INC Injectable flowable composition comprising buprenorphine
Jun, 2031

(8 years from now)

US10592168 INDIVIOR INC Injectable flowable composition comprising buprenorphine
Jun, 2031

(8 years from now)

US9827241 INDIVIOR INC Injectable flowable composition comprising buprenorphine
Jun, 2031

(8 years from now)

US9782402 INDIVIOR INC Injectable composition comprising buprenorphine
Jun, 2031

(8 years from now)

US10558394 INDIVIOR INC Injectable flowable composition comprising buprenorphine
Jun, 2031

(8 years from now)

US8975270 INDIVIOR INC Injectable flowable composition comprising buprenorphine
Sep, 2031

(8 years from now)

US8921387 INDIVIOR INC Injectable flowable composition comprising buprenorphine
Jan, 2032

(8 years from now)

US11000520 INDIVIOR INC Buprenorphine dosing regimens
Nov, 2035

(12 years from now)

US10646484 INDIVIOR INC Methods to treat opioid use disorder
Jun, 2038

(15 years from now)

Drugs and Companies using BUPRENORPHINE ingredient

Market Authorisation Date: 30 November, 2017

Treatment: Treatment of moderate to severe opioid use disorder; Treating opioid addiction by administering buprenorphine; Treating opioid addiction by administering buprenorphine once per month; Treating opioid addiction by administering buprenorphine composition with 28 day dose duration; Treating opioid addiction by subcutaneous injection of buprenorphine; In situ formation of solid buprenorphine composition; Treating opioid dependency by administering buprenorphine; Treating opioid addiction by administration of buprenorphine; Treating opioid dependency by subcutaneously administering buprenorphine; Treating opioid addiction by 100 mg or 300 mg dose buprenorphine; Treating opioid dependency by administering buprenorphine once per month; Treating addiction with 100 mg or 300 mg dose of buprenorphine; Treating addiction by once per month administration of buprenorphine; Treating addiction by subcutaneous injection of buprenorphine; Treating opioid dependency by administering buprenorphine once monthly; Treating opioid dependence by administering buprenorphine; Treating opioid use disorder

Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic